Immunovant, Inc. (IMVT) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Immunovant, Inc. (IMVT) posted $0 in revenue for fiscal 2026, with a net loss of $505.61M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Immunovant, Inc.
Immunovant, Inc. has grown revenue from $0 to $0 over the last 8 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Immunovant, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Immunovant, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-28.60M | $-66.39M | $-107.43M | $-156.73M | $-210.96M | $-259.34M | $-413.84M | $-505.61M |
| Net margin | — | — | — | — | — | — | — | — |
Source: Immunovant, Inc. SEC filings (10-K).
Immunovant, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 75.1% over 4 years (116.5M → 203.9M) — existing holders' stakes are being diluted.
Explore 8 years of Immunovant, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IMVT in your portfolio →
Immunovant, Inc. financial history by metric
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc. — frequently asked questions
What is Immunovant, Inc.'s revenue?
Immunovant, Inc. (IMVT) reported revenue of $0 for fiscal year 2026, according to its SEC filings.
Is Immunovant, Inc. profitable?
No — IMVT reported a net loss of $-505.61M in fiscal 2026.
What is IMVT's P/E ratio?
Immunovant, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Immunovant, Inc. have?
As of fiscal year 2026, IMVT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Immunovant, Inc.'s market cap?
Immunovant, Inc. (IMVT) has a market capitalization of about $6.65B, based on the latest data in our nightly-refreshed cache.
When does Immunovant, Inc.'s fiscal year end?
IMVT's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2026-03-31.
Where does this data come from?
All figures are computed from Immunovant, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.